$EMCG
Embrace Change Acquisition Corp

2023 Q3 Form 10-Q Financial Statement

#000119312523210726 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $488.0K $120.8K $199.8K
YoY Change 216.4%
Operating Profit -$488.0K -$120.8K
YoY Change 216.4%
Interest Expense $942.8K $941.2K $641.1K
YoY Change 662.88%
% of Operating Profit
Other Income/Expense, Net $942.8K $941.2K
YoY Change
Pretax Income $454.8K $820.4K $441.3K
YoY Change -1583.37%
Income Tax
% Of Pretax Income
Net Earnings $454.8K $820.4K $441.3K
YoY Change -1583.51%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.08
Diluted Earnings Per Share -$0.05 -$0.08 $0.05
COMMON SHARES
Basic Shares Outstanding 8.138M 9.689M 9.689M
Diluted Shares Outstanding 9.109M 9.689M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.210K $287.2K $403.0K
YoY Change -98.08%
Cash & Equivalents $9.208K $287.2K $403.0K
Short-Term Investments
Other Short-Term Assets $17.50K $35.00K
YoY Change
Inventory
Prepaid Expenses $17.50K $35.00K $0.00
Receivables
Other Receivables
Total Short-Term Assets $26.71K $322.2K $403.5K
YoY Change -94.43% 138.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $64.06M $78.30M $76.54M
YoY Change -15.6%
Other Assets $0.00
YoY Change
Total Long-Term Assets $64.06M $78.30M $76.54M
YoY Change -15.6% 43103.23%
TOTAL ASSETS
Total Short-Term Assets $26.71K $322.2K $403.5K
Total Long-Term Assets $64.06M $78.30M $76.54M
Total Assets $64.09M $78.63M $76.94M
YoY Change -16.09% 43280.99% 45416.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $918.2K $324.8K
YoY Change
Accrued Expenses $157.1K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $10.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $928.2K $324.8K $157.1K
YoY Change 2701.42% 103.64% 6.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.588M $2.588M $2.588M
YoY Change 0.0%
Total Long-Term Liabilities $2.588M $2.588M $2.588M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $928.2K $324.8K $157.1K
Total Long-Term Liabilities $2.588M $2.588M $2.588M
Total Liabilities $3.516M $2.912M $2.745M
YoY Change 34.15% 1720.16% 1763.49%
SHAREHOLDERS EQUITY
Retained Earnings -$3.489M -$2.590M -$2.341M
YoY Change 62.94% 80095.23% 72384.43%
Common Stock $230.00 $230.00 $230.00
YoY Change 0.0% 22.99% 22.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.489M -$2.590M -$2.341M
YoY Change
Total Liabilities & Shareholders Equity $64.09M $78.63M $76.94M
YoY Change -16.09% 43280.99% 45416.11%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income $454.8K $820.4K $441.3K
YoY Change -1583.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$87.97K -$111.3K -$76.40K
YoY Change -27.36% -158.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $15.19M $0.00
YoY Change -120.04%
Cash From Investing Activities $15.19M $0.00
YoY Change -120.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.38M 0.000 0.000
YoY Change -120.13% -100.0%
NET CHANGE
Cash From Operating Activities -87.97K -111.3K -76.40K
Cash From Investing Activities 15.19M 0.000
Cash From Financing Activities -15.38M 0.000 0.000
Net Change In Cash -15.46M -111.3K -76.40K
YoY Change -3356.79%
FREE CASH FLOW
Cash From Operating Activities -$87.97K -$111.3K -$76.40K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001869601
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
EMBRACE CHANGE ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity File Number
EntityFileNumber
001-41397
dei Entity Address Address Line1
EntityAddressAddressLine1
5186 Carroll Canyon Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
688-4965
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8138038
CY2023Q2 us-gaap Cash
Cash
287183
CY2022Q4 us-gaap Cash
Cash
403012
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
0
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
521
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35002
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2023Q2 us-gaap Assets Current
AssetsCurrent
322185
CY2022Q4 us-gaap Assets Current
AssetsCurrent
403533
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
78304986
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
76541453
CY2023Q2 us-gaap Assets
Assets
78627171
CY2022Q4 us-gaap Assets
Assets
76944986
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
324762
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
157051
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
324762
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
157051
CY2023Q2 emcgu Deferred Underwriter Fee Payable Non Current
DeferredUnderwriterFeePayableNonCurrent
2587499
CY2022Q4 emcgu Deferred Underwriter Fee Payable Non Current
DeferredUnderwriterFeePayableNonCurrent
2587499
CY2023Q2 us-gaap Liabilities
Liabilities
2912261
CY2022Q4 us-gaap Liabilities
Liabilities
2744550
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7392855
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7392855
CY2023Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.59
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.35
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
78304986
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
76541453
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
230
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
230
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2590306
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2341247
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2590076
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2341017
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78627171
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76944986
CY2023Q2 emcgu Formation And Operating Costs
FormationAndOperatingCosts
120796
CY2022Q2 emcgu Formation And Operating Costs
FormationAndOperatingCosts
0
emcgu Formation And Operating Costs
FormationAndOperatingCosts
249059
emcgu Formation And Operating Costs
FormationAndOperatingCosts
0
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-120796
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-249059
us-gaap Operating Income Loss
OperatingIncomeLoss
0
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
941216
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
0
us-gaap Investment Income Net
InvestmentIncomeNet
1763533
us-gaap Investment Income Net
InvestmentIncomeNet
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
820420
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
0
us-gaap Net Income Loss
NetIncomeLoss
1514474
us-gaap Net Income Loss
NetIncomeLoss
0
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9688748
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9688748
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1848214
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1848214
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9688748
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9688748
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1848214
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1848214
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2341017
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
694054
CY2023Q1 emcgu Remeasurement Of Ordinary Shares Subject To Redemption
RemeasurementOfOrdinarySharesSubjectToRedemption
822317
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2469280
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
820420
CY2023Q2 emcgu Remeasurement Of Ordinary Shares Subject To Redemption
RemeasurementOfOrdinarySharesSubjectToRedemption
941216
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2590076
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21770
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
0
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21770
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
0
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21770
us-gaap Net Income Loss
NetIncomeLoss
1514474
us-gaap Net Income Loss
NetIncomeLoss
0
us-gaap Investment Income Net
InvestmentIncomeNet
1763533
us-gaap Investment Income Net
InvestmentIncomeNet
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-521
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
35002
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
167711
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-115829
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-115829
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403012
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4602
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
287183
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3602
emcgu Remeasurement Of Ordinary Shares Subject To Redemption
RemeasurementOfOrdinarySharesSubjectToRedemption
1763533
emcgu Remeasurement Of Ordinary Shares Subject To Redemption
RemeasurementOfOrdinarySharesSubjectToRedemption
0
emcgu Deferred Offering Costs Included In Promissory Note
DeferredOfferingCostsIncludedInPromissoryNote
0
emcgu Deferred Offering Costs Included In Promissory Note
DeferredOfferingCostsIncludedInPromissoryNote
12198
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3898030
CY2022Q3 emcgu Deferred Underwriter Fee Payable Non Current
DeferredUnderwriterFeePayableNonCurrent
2587499
CY2022Q3 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
75776764
CY2022Q3 emcgu Restricted Investment Price Per Share
RestrictedInvestmentPricePerShare
10.25
CY2023Q2 us-gaap Share Price
SharePrice
10.25
CY2023Q2 emcgu Percentage Of Public Shares To Be Redeemed On Non Completion Of Business Combination
PercentageOfPublicSharesToBeRedeemedOnNonCompletionOfBusinessCombination
1
emcgu Dissolution Expense
DissolutionExpense
50000
CY2023Q2 us-gaap Share Price
SharePrice
10.25
CY2023Q2 us-gaap Cash
Cash
287183
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
159478
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
159478
CY2023Q2 us-gaap Cash
Cash
287183
CY2022Q4 us-gaap Cash
Cash
403012
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
78304986
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
76541453
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3898030
CY2023Q2 emcgu Deferred Underwriter Fee Payable Non Current
DeferredUnderwriterFeePayableNonCurrent
2587499
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
571245
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7392855
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. On June 30, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. On June 30, 2023, the Company had $287,183 cash held in operating bank account. </div>
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q2 us-gaap Cash
Cash
287183
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
820420
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
0
us-gaap Net Income Loss
NetIncomeLoss
1514474
us-gaap Net Income Loss
NetIncomeLoss
0
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9688748
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9688748
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1848214
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1848214
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9688748
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9688748
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1848214
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1848214
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3898030
CY2022Q3 emcgu Deferred Underwriter Fee Payable Non Current
DeferredUnderwriterFeePayableNonCurrent
2587499
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3737500
CY2022Q3 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
159478
emcgu Underwriting Discount Percentage
UnderwritingDiscountPercentage
-0.01
emcgu Deferred Underwriting Commission Percentage
DeferredUnderwritingCommissionPercentage
-0.035
emcgu Percenatge Of Gross Proceeds Of The Ordinary Shares
PercenatgeOfGrossProceedsOfTheOrdinaryShares
0.01
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1437500
CY2021Q4 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
0.5
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295893
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295893
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7392855
emcgu Warrants Not Exercisable Term From The Consummation Of Business Combination
WarrantsNotExercisableTermFromTheConsummationOfBusinessCombination
P90D
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1/8

Files In Submission

Name View Source Status
0001193125-23-210726-index-headers.html Edgar Link pending
0001193125-23-210726-index.html Edgar Link pending
0001193125-23-210726.txt Edgar Link pending
0001193125-23-210726-xbrl.zip Edgar Link pending
d539680d10q.htm Edgar Link pending
d539680dex311.htm Edgar Link pending
d539680dex312.htm Edgar Link pending
d539680dex321.htm Edgar Link pending
d539680dex322.htm Edgar Link pending
emcgu-20230630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
emcgu-20230630_def.xml Edgar Link unprocessable
emcgu-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
emcgu-20230630_lab.xml Edgar Link unprocessable
d539680d10q_htm.xml Edgar Link completed
emcgu-20230630_cal.xml Edgar Link unprocessable